Biomarker for the medicine and the biology of the reproduction

A sample, serum technology, used in predictive markers, reproductive medicine and biology, to solve problems such as difficult evaluation

Inactive Publication Date: 2010-02-03
UNIV DAIX MARSEILLE
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It is difficult to assess the intrinsic ability of the embryo to release a set of signals that support its implantation in the endometrium

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarker for the medicine and the biology of the reproduction
  • Biomarker for the medicine and the biology of the reproduction
  • Biomarker for the medicine and the biology of the reproduction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0073] Example 1: Serum levels of soluble MIC are predictive markers of implantation failure and successful term pregnancy following in vitro fertilization.

[0074] Uterine NK (uNK) is the major lymphocyte population found at the implantation site of the embryo and progressively disappears after the second trimester. Thus, intrinsic immune mechanisms at work in the mother are thought to have a powerful influence in the acceptance of a hemi-allogeneic fetus. In particular, uNK receptors recognize parental / trophoblast ligands that protect the fetus from attack by the maternal immune system.

[0075]The presence in embryonic supernatants of soluble HLA-G, a known NK-inhibiting ligand that is normally expressed at the fetal-maternal interface, is associated with higher embryo implantation rates after in vitro fertilization (IVF) (Fuzzi et al., 2002 ; Warner et al., 2004). Interactions between killer cell immunoglobulin receptors (KIRs) on maternal uNK and fetal HLA-C also affec...

Embodiment 2

[0105] Example 2: High Frequency of Soluble MIC Found in Plasma of Women with Vascular Pregnancy Disease

[0106] Pregnancy creates a unique state in which extensive angiogenesis and the establishment of maternal immune tolerance allow successful fetal and placental development. Communication between trophoblast fetal cells and maternal immune cells regulates placental development, angiogenesis, and fetal immune tolerance in early pregnancy. Insufficient placenta formation leads to vascular pregnancy disorders (VPD), including preeclampsia (PE), intrauterine growth retardation (IUGR) and recurrent pregnancy loss, which represent a major cause of feto-maternal morbidity and mortality. Preeclampsia is characterized by high blood pressure and proteinuria after 20 weeks of pregnancy. Despite recent advances in understanding how inadequate placental vascularization (incomplete remodeling of the spiral arteries) can lead to vascular pregnancy disorders, their prognosis remains seve...

Embodiment 2a

[0108] Materials and methods

[0109] subjects

[0110] Soluble MIC plasma levels were evaluated in 49 women who experienced vascular pregnancy disease (VPD), including vascular intrauterine growth retardation (IUGR), preeclampsia (PE) or intrauterine fetal death (IUFD) , and compared to a plasma control group from 53 women with normally undergoing pregnancies matched for gestational duration (mean 29 weeks).

[0111] method

[0112] PE is defined as arterial diastolic blood pressure greater than 90mm Hg, systolic blood pressure greater than 140mmHg, combined with proteinuria (more than 300mg / 24h). In addition, serious maternal complications associated with an increased risk of adverse maternal and fetal outcomes, particularly associated with HELLP syndrome (H = hemolysis; EL = increased liver enzymes; and LP = low platelets) have been reported (Weinstein et al., 2005 ) and oliguria leading to renal failure.

[0113] Vascular IUGR was defined as measured by sonography, ges...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a new biomarker for the medicine and the biology of reproduction, in particular for in vitro fertilization (IVF) outcome. It relates to methods for predicting IVF outcome and for selecting the subject for IVF.

Description

field of invention [0001] The present invention relates to reproductive medicine and biology. The present invention relates to predictive markers of implantation failure and successful term pregnancy, especially after in vitro fertilization. Background of the invention [0002] The diagnosis and management of infertility is a common health problem in young adults. For infertile couples, the developing technology of in vitro fertilization (IVF) is a promising fertility alternative. However, in vitro fertilization is associated with an increased risk of clinical complications, which represent disadvantages for their manifestation in women, including the risk of multiple births, spontaneous abortion of ectopic pregnancies, and preterm birth. Considering these clinical risks, and the high economic cost of these high-end technologies, IVF treatment remains difficult for most infertile couples. Although a better understanding of the mechanisms affecting fertilization and implan...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68
CPCG01N2800/367G01N2333/70539G01N2800/368G01N33/689Y10T436/143333
Inventor 帕斯卡尔·保罗索菲·卡亚·楚克曼杰拉尔丁·波尔库
Owner UNIV DAIX MARSEILLE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap